Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

Efficacy of tenofovir dipivoxil plus entecavir in patients with HBeAg positive chronic hepatitis B

Xiang Deng, Hua Liu , Zaihui Jiang

Department of Infectious Disease, The First People's Hospital of Jiangxia District, Wuhan City (Union Jiangnan Hospital Huazhong University of Science and Technology), Wuhan, Hubei Province 430200, China;

For correspondence:- Hua Liu Email: liuhua3101301@163.com Tel:+8615872026283

Accepted: 6 July 2024 Published: 31 July 2024

Citation: Deng X, Liu H, Jiang Z. Efficacy of tenofovir dipivoxil plus entecavir in patients with HBeAg positive chronic hepatitis B. Trop J Pharm Res 2024; 23(7):1111-1117 doi: 10.4314/tjpr.v23i7.9

© 2024 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To investigate the efficacy of tenofovir disoproxil fumarate (TDF) plus entecavir in patients with HBeAg positive chronic hepatitis B.

Methods: A total of 124 patients with HBeAg-positive chronic hepatitis who were hospitalized at The First People's Hospital of Jiangxia District, Wuhan, China were chosen as the subjects. They were then randomized equally into study and control groups. Control group received entecavir (0.5 mg orally) while the study group administered TDF (300 mg orally) daily for 48 weeks. Efficacy, liver function, inflammatory factors, liver fibrosis, and adverse reactions between the two groups were evaluated.

Results: After 12 weeks of treatment, HBeAg and HBV DNA negative seroconversion rates were significantly higher in the study group compared to control group (p < 0.05). At 24 and 48 weeks after treatment, alanine transaminase (ALT) normalization rate, HBeAg and HBV DNA negative seroconversion rate were also significantly higher compared to control group. Levels of heat shock protein 47 (HSP47), endothelial nitric oxide synthase (eNOS), and major basic protein (MBP) were significantly lower in study group compared to control group. Levels of hyaluronan (HA), type IC collagen (IV-C), N-terminal propeptide of procollagen type III (PIIINP), and laminin (LN) were significantly lower in study group compared to control group (p < 0.05). There was no significant difference in incidence of adverse reactions between the two groups (p > 0 05).

Conclusion: The combination of ETV and TDF significantly inhibits hepatitis B virus replication, and reduces inflammatory reactions. Further studies to determine the mechanism of action of tenofovir and entecavir on hepatitis B virus would be required.

Keywords: Tenofovir disoproxil fumarate, Entecavir, High viral load, HBeAg positive, Chronic hepatitis B